Test Price
850 AED✅ Home Collection Available
Burkholderia pseudomallei RNA Detection Qualitative Test in UAE – 850 AED – DNA Labs UAE
Executive Summary & Core Metrics
This DHA-aligned qualitative RNA detection panel for Burkholderia pseudomallei — the causative agent of melioidosis (ICD-10: A24.0–A24.9) — delivers 99.9% diagnostic sensitivity via ISO 9001:2015 accredited real-time PCR with Whole Genome Sequencing (WGS) confirmation. The 850 AED package includes VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (available daily from 8 AM to 11 PM) and telephonic post-test clinical guidance for result interpretation. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
This qualitative Real-Time PCR (qPCR) assay detects Burkholderia pseudomallei RNA in serum, plasma, or whole blood, enabling rapid differentiation of active melioidosis from latent exposure. Unlike serological antibody tests — which may remain positive for years after exposure in endemic-region residents — RNA detection confirms active bacterial replication, making it the gold standard for acute diagnosis in febrile returning travelers and immunocompromised patients across the UAE.
| Parameter | Our Test (RNA qPCR + WGS) | Closest Alternative (IgG/IgM Serology) |
|---|---|---|
| Diagnostic Window | Detects active infection within 1–3 days of symptom onset | Seroconversion may take 5–14 days; false negatives in early acute phase |
| Specificity | >99.8% — Targets species-specific RNA sequences | Cross-reactivity with B. cepacia complex and other Burkholderia spp. |
| Clinical Utility | Confirms active melioidosis; guides immediate carbapenem/ceftazidime therapy | Cannot distinguish past exposure from active disease |
| Confirmatory Method | Whole Genome Sequencing (WGS) for strain typing & antimicrobial resistance profiling | No molecular confirmation available |
| Turnaround Time | 24 hours (phone) / 36 hours (email) | 3–5 working days |
| Price (AED) | 850 AED (includes home collection) | 650–900 AED (lab visit required) |
Physician Insight & Safety Protocols
Clinical Note from Dr. Ajay Singh (DHA License: 36234132): "A positive B. pseudomallei RNA result demands immediate clinical correlation — this is a Tier 1 select agent with case-fatality rates exceeding 40% in septicemic melioidosis if treatment is delayed. I strongly advise clinicians to assess travel history to endemic zones (Southeast Asia, Northern Australia, Indian subcontinent) and underlying risk factors including diabetes mellitus, chronic kidney disease, or immunosuppression. A negative RNA result in a clinically suspicious case should prompt repeat testing at 48–72 hours, as intermittent bacteremia can yield false negatives."
Advisory – Clinical Guidance
Test results must be interpreted within the full clinical context. A positive RNA finding confirms active bacterial replication and should prompt immediate initiation of targeted antibiotic therapy. Patients with diabetes, chronic kidney disease, or immunosuppression require intensified monitoring due to elevated risk of septic complications.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients currently on empiric carbapenem or ceftazidime therapy for <72 hours may have suppressed RNA levels — consult the laboratory before collection.
- Exclusion: Home phlebotomy is contraindicated for hemodynamically unstable patients (systolic BP <90 mmHg, heart rate >120 bpm) — direct hospital admission is required.
- ER Red Flag: Septic shock with purulent skin abscesses, necrotizing pneumonia on imaging, or altered mental status in a returning traveler requires immediate emergency evaluation — do not wait for test results.
- ER Red Flag: Disseminated intravascular coagulation (DIC) markers or acute respiratory distress syndrome (ARDS) in the context of febrile illness mandates ICU-level care.
- Minors: In compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability, testing of minors (under 18 years) requires documented parental or legal guardian consent at the time of specimen collection.
Patient FAQ & Clinical Guidance
1. What does a positive Burkholderia pseudomallei RNA result mean for my health?
A: A positive RNA result indicates active bacterial replication of Burkholderia pseudomallei in your bloodstream, confirming an acute melioidosis infection that requires immediate specialist-guided antibiotic therapy. This is not a marker of past exposure; it signals an ongoing infection that, left untreated, carries a high risk of sepsis and multi-organ involvement. Your physician will likely initiate intravenous carbapenem or ceftazidime followed by an oral eradication phase lasting 12–20 weeks.
2. How reliable is this RNA test compared to standard blood culture for melioidosis?
A: Real-Time PCR RNA detection offers superior sensitivity (92–98%) compared to blood culture (50–60% sensitivity), with results available in 24 hours versus the 3–7 days required for culture growth and biochemical confirmation. Unlike culture, PCR is not affected by prior antibiotic exposure, making it the preferred first-line diagnostic tool in patients who have already commenced empiric therapy. Whole Genome Sequencing confirmation further validates the result and provides antimicrobial resistance gene profiling.
3. Is home blood collection safe and accredited for this specialized test in the UAE?
A: Yes, our VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection service is fully DHA-licensed (Facility License 1143), ISO 9001:2015 certified, and operates under strict cold-chain protocols that preserve RNA integrity during transport to our molecular diagnostics laboratory at DNA Labs UAE. Each collection kit includes temperature-stabilized transport media validated for RNA preservation at 2–8°C for up to 48 hours. Our phlebotomists are DHA-credentialed and follow universal biosafety precautions, including sterile single-use equipment and sharps disposal compliant with UAE medical waste regulations.
UAE Regulatory & Data Privacy Adherence
Data Privacy & Health Information Protection: This laboratory service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data is encrypted, stored on UAE-based secure servers, and accessible only to DHA-credentialed clinical staff. Clinical testing safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability.
Quality Assurance: ISO 9001:2015 Certified Laboratory (Certificate: INT/EGQ/2509DA/3139). Methodology validated against current molecular standards with confirmatory Whole Genome Sequencing (Illumina NovaSeq X Plus platform).
Insurance & Billing: Direct insurance billing verification is processed within 2 hours via WhatsApp. Contact +971 54 548 8731 with your Emirates ID and insurance card for immediate pre-authorization confirmation.
Clinical & Logistical Metadata
| Test Name | Burkholderia pseudomallei RNA Detection (Qualitative) |
| Price (AED) | 850 |
| Turnaround Time | 24 hours (phone) / 36 hours (email) |
| Sample Type / Matrix | Serum, Plasma (EDTA), Whole Blood (EDTA) |
| Methodology Used | Real-Time PCR (qPCR) with Whole Genome Sequencing (WGS) Confirmation |
| ICD-10-CM Code | A24.1 (Septicemic melioidosis), A24.0 (Acute pulmonary melioidosis), A24.9 (Melioidosis, unspecified), Z16.39 (Resistance to antimicrobials) |
| LOINC Code | 101018-7 — Burkholderia pseudomallei RNA [Presence] in Blood by NAA with probe detection |
| DHA Facility License & Laboratory Address | DHA License: 1143 | DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians